This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Background and Date of Approval
Dolutegravir, Lamivudine and Tenofovir disoproxil Fumarate is a combination regimen consisting of antiviral medications, which was approved for its medical use on 13th April 2020.
Mechanism of Action of undefined
Dolutegravir, Lamivudine and Tenofovir disoproxil Fumarate Tablet is a combination of integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitors. It works by increasing the number of CD4 T cells and stimulates the immune system to fight against infections. Thereby, it reduces the viral load of HIV in the blood and decreases the severity of HIV infection.
Uses of undefined
Dolutegravir, Lamivudine and Tenofovir disoproxil Fumarate has been developed to treat Human Immunodeficiency Virus (HIV-1). Dolutegravir, Lamivudine and Tenofovir disoproxil Fumarate Tablet is indicated as a complete regimen for treating adults and children infected with HIV 1.
undefined Drug administaration and Dosage available
Dolutegravir, Lamivudine and Tenofovir disoproxil fumarate is available as film coated tablets consisting of 50mg of Dolutegravir, 300mg of Lamivudine and 300mg of Tenofovir disoproxil fumarate. The usual recommended dosage of this combination regimen is one tablet everyday with or without food.
Warnings, Precautions and Side Effects of undefined
Do not take this medication if you have experienced hypersensitivity reactions to Dolutegravir, lamivudine or Tenofovir disoproxil fumarate. Patients who are diagnosed with pancreatitis or at risk of pancreatitis should take this combination medicine with caution. During the Dolutegravir, Lamivudine and Tenofovir disoproxil Fumarate Tablet treatment, your doctor may periodically monitor your blood counts, bone mineral density, liver and kidney parameters to prevent serious complications. Report to your doctor if you have had a history of heart failure, pancreatitis, bone disease, fractures, liver or kidney problems.
Adults of childbearing potential should consider using an effective contraceptive to prevent unwanted pregnancy. If you are pregnant or think you might be pregnant, your physician might suggest an alternative treatment as this combination regimen is not recommended during early pregnancy. Breastfeeding is not recommended due to potential transmission of HIV from mother to the baby.
The common side effects that are likely to occur while you are on the treatment with Dolutegravir, Lamivudine and Tenofovir disoproxil Fumarate Tablet are insomnia, tiredness, headache, diarrhoea, rash, pain, depression, cough and fever. Some serious adverse reactions include bone loss, worsening of Hepatitis B, kidney injury, immune reconstitution syndrome, lactic acidosis, and severe hepatomegaly. If you experience any allergic reactions after taking this tablet, report to your doctor immediately.
Word Of Advice
Dolutegravir, Lamivudine and Tenofovir disoproxil Fumarate can make you feel tired. Hence, you should avoid driving or handling machines during this treatment.
Frequently Asked Question
- KD Tripathi, Antiviral Drugs (Anti-retrovirus), Essentials of Medical Pharmacology, 8th Edition, 2019, 860-872.
- Lorus Generics Inc., U.S. Food and Drug Administration, [Revised on Jan 2021] [Accessed on 27th Aug 2022], https://www.accessdata.fda.gov/drugsatfda_docs/pepfar/210787PI.pdf
- Adis International Ltd., Springer Nature, [Accessed on 27th Aug 2022], https://adisinsight.springer.com/drugs/800058512
The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details consult your doctor about your medical condition to know if you are eligible to receive this treatment.